Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Research Report 2024
Acral erythema, also called as hand-foot syndrome or palmar-plantar erythrodysesthesia, is characterized by swelling, redness, paraesthesia (numbness) and desquamation (skin peeling) of palms, soles and rarely on knees and elbow. Acryl erythema is an adverse drug reaction which typically appear after several months of treatment with chemotherapeutic agents, gemcitabine and fluorouracil being the most common drugs causing reaction. Chemotherapy induced acryl erythema is a dose dependent condition, regression of which can be achieved by discontinuation of chemotherapy or by dose reduction. Treatment for chemotherapy induced acryl erythema includes symptomatic treatment with analgesics and antihistaminic drugs to reduce pain and edema.
According to MRAResearch’s new survey, global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment market research.
Surge in usage of chemotherapeutic agents due to increasing incidence of cancers is the major growth driver of global chemotherapy induced acral erythema treatment market.Moreover, lifestyle up-gradation, increasing number of smokers are some secondary considerations accountable for rise in global chemotherapy induced acral erythema treatment market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Taro
Oceanside Pharmaceuticals
Pfizer
Novartis
A-S Medication Solutions
Preferred Pharmaceuticals
Syntex Pharmaceuticals
Valeant Canada
Technilab Pharma
Allergan
Segment by Type
Analgesics
Anti-Inflammatory And Anti-Edematous Agents
Antihistaminic
NSAIDs
Oral/Topical Glucocorticoids
Pyridoxine (Vitamin B6)
Others
Pharmacy And Drugstores
Hospital Pharmacy
Online Drug Stores
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment market research.
Surge in usage of chemotherapeutic agents due to increasing incidence of cancers is the major growth driver of global chemotherapy induced acral erythema treatment market.Moreover, lifestyle up-gradation, increasing number of smokers are some secondary considerations accountable for rise in global chemotherapy induced acral erythema treatment market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Taro
Oceanside Pharmaceuticals
Pfizer
Novartis
A-S Medication Solutions
Preferred Pharmaceuticals
Syntex Pharmaceuticals
Valeant Canada
Technilab Pharma
Allergan
Segment by Type
Analgesics
Anti-Inflammatory And Anti-Edematous Agents
Antihistaminic
NSAIDs
Oral/Topical Glucocorticoids
Pyridoxine (Vitamin B6)
Others
Segment by Application
Pharmacy And Drugstores
Hospital Pharmacy
Online Drug Stores
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source